EV68-228-N is under clinical development by KBio and currently in Phase I for Flaccid Paralysis. According to GlobalData, Phase I drugs for Flaccid Paralysis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the EV68-228-N LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
EV68-228-N overview
EV68-228-N is under development for the treatment of EV-D68 infection and acute flaccid myelitis (AMF). It is a monoclonal antibody acts against enterovirus EV-D68 capsid protein and is administered through intravenous route. It is being developed based on RP3 platform.
KBio overview
KBio, Inc. is a Pharmaceuticals and Healthcare company that provides drug development services. The company is Headquartered in Owensboro, Kentucky, The U.S.
For a complete picture of EV68-228-N’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
